1. Home
  2. CAC vs NRIX Comparison

CAC vs NRIX Comparison

Compare CAC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • NRIX
  • Stock Information
  • Founded
  • CAC 1875
  • NRIX 2009
  • Country
  • CAC United States
  • NRIX United States
  • Employees
  • CAC N/A
  • NRIX N/A
  • Industry
  • CAC Major Banks
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAC Finance
  • NRIX Health Care
  • Exchange
  • CAC Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • CAC 680.5M
  • NRIX 750.4M
  • IPO Year
  • CAC 1997
  • NRIX 2020
  • Fundamental
  • Price
  • CAC $37.71
  • NRIX $11.14
  • Analyst Decision
  • CAC Buy
  • NRIX Strong Buy
  • Analyst Count
  • CAC 3
  • NRIX 14
  • Target Price
  • CAC $48.00
  • NRIX $26.64
  • AVG Volume (30 Days)
  • CAC 75.5K
  • NRIX 1.6M
  • Earning Date
  • CAC 10-28-2025
  • NRIX 10-09-2025
  • Dividend Yield
  • CAC 4.46%
  • NRIX N/A
  • EPS Growth
  • CAC 4.80
  • NRIX N/A
  • EPS
  • CAC 3.11
  • NRIX N/A
  • Revenue
  • CAC $197,501,000.00
  • NRIX $83,687,000.00
  • Revenue This Year
  • CAC $42.11
  • NRIX $58.48
  • Revenue Next Year
  • CAC $5.51
  • NRIX N/A
  • P/E Ratio
  • CAC $12.09
  • NRIX N/A
  • Revenue Growth
  • CAC 21.74
  • NRIX 48.32
  • 52 Week Low
  • CAC $34.53
  • NRIX $8.18
  • 52 Week High
  • CAC $50.07
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • CAC 48.46
  • NRIX 60.81
  • Support Level
  • CAC $36.65
  • NRIX $10.28
  • Resistance Level
  • CAC $37.44
  • NRIX $11.70
  • Average True Range (ATR)
  • CAC 1.09
  • NRIX 0.77
  • MACD
  • CAC 0.06
  • NRIX 0.14
  • Stochastic Oscillator
  • CAC 57.99
  • NRIX 77.04

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: